Monday, January 15, 2024 12:00 PM to 1:40 PM
Wilentz Shareholder Michael F. Schaff, co-chair of the Corporate, Health, and Cannabis law practice groups, Past Chair of the NJSBA Health Law Section, and NJSBA Trustee, will moderate the program entitled “Experiential Use of Generative AI in Healthcare.” The program will review the difference between Generative Artificial Intelligence and Artificial Intelligence, and bring into focus the inherent risks and potential utility of generative artificial intelligence models.
This seminar marks the beginning of a series to provide insight to practitioners working in healthcare and other legal fields and attendees across the entire range of regulatory, transactional, litigators, in-house counsel, consultants, lobbyists, and those who provide compliance services.
The program agenda includes:
For more information and to register, please visit the event page.
This program has been approved by the Board on Continuing Legal Education of the Supreme Court of New Jersey for 2 hours of total CLE credit (Full Credits Available: NJ General: 2.0).
*Cannabis Law Disclaimer: Per federal law, under the Controlled Substances Act, marijuana is categorized as a Schedule I controlled substance. Possession, use, distribution, and/or sale of cannabis is a Federal crime and is subject to related Federal policy, regardless of any state law that may authorize certain marijuana activity. Compliance with state marijuana law does not equal compliance with federal law. Legal advice provided by Wilentz, Goldman & Spitzer, P.A. is designed to counsel clients regarding the validity, scope, meaning, and application of existing and/or proposed cannabis law. Wilentz, Goldman & Spitzer, P.A. will not provide guidance or assistance in circumventing or violating Federal or state cannabis law or policy, and any advice provided by Wilentz, Goldman & Spitzer, P.A. should not be construed as such.
Michael F. Schaff
Co-Chair, Corporate, Health and Cannabis Law Teams
Shareholder
732.855.6047